Engineering T Cells with a Membrane-Tethered Version of SLP-76 Overcomes Antigen-Low Resistance to CAR T Cell Therapy

Researchers developed a platform that endows CAR T cells with the ability to kill antigen-low cancer cells consisting of a membrane-tethered version of the cytosolic signaling adaptor molecule SLP-76.